Robust Outcomes Shown with Whole Gland Ablation for Treatment of Clinically Localized Prostate Cancer

Duke Urology’s Thomas Polascik, MD, and colleagues published a white paper in European Urology that shows good intermediate- to long-term outcomes for patients with low- to intermediate-risk localized prostate cancer.

The study was a systematic review and meta-analysis of 14 cryoablation studies and 15 high-intensity focused ultrasound studies published from 2000 to 2021.

The reviewers found that whole gland ablation is a good option for low- to intermediate-risk patients who are ineligible for radiation, surgery, or focal ablation.

Read a summary of the publication.